BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and ...
Novel drug visualizing technology in human tumor specimens using mass spectrometry to support/enhance early-phase drug development. This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I ...
Aging-US Issue 1 Volume 13 features "PAM (PIK3/AKT/mTOR) signaling in glia: potential contributions to brain tumors in aging" which reported that despite a growing proportion of aged individuals at ...
Gedatolisib is the first approved agent to inhibit class I PI3K isoforms plus both mTOR complexes, addressing a long-standing challenge in comprehensive PI3K/AKT/mTOR pathway blockade. The indication ...
Novartis Oncology is investigating the PI3K/AKT/mTOR pathway to understand and treat advanced breast cancer. Touching Base is the dynamic podcast series from the editors of GEN. Each episode features ...
MedPage Today on MSN
PAM inhibitor approved for HR-positive breast cancer
Gedatolisib is approved in combination with fulvestrant, with or without palbociclib ...
FDA Approves Celcuity's Revtorpyk Combo in HR-Positive, HER2-Negative, PIK3CA Wildtype Breast Cancer
The FDA approved the PI3K/AKT/mTOR inhibitor Revtorpyk with fulvestrant and with or without Pfizer's CDK4/6 Ibrance based on Phase III data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results